[Case of a Patient with Inflammatory Breast Cancer Who Responded to Preoperative Chemotherapy with Paclitaxel plus Bevacizumab and Could Subsequently Undergo Surgery].

Gan to kagaku ryoho. Cancer & chemotherapy

PubMedID: 24394120

Kashiwagi S, Ishihara S, Ishii M, Asano Y, Watanabe M, Morisaki T, Aomatsu N, Noda S, Kawajiri H, Nakano T, Kawakami N, Mitsukawa Y, Takashima T, Onoda N, Ishikawa T, Hirakawa K. [Case of a Patient with Inflammatory Breast Cancer Who Responded to Preoperative Chemotherapy with Paclitaxel plus Bevacizumab and Could Subsequently Undergo Surgery]. Gan To Kagaku Ryoho. 2013;40(12):2384-6.
A 58-year-old woman observed swelling in her left breast a few weeks prior to presentation. Rigidity in the D area, breast warmth, swelling, and a peau d'orange appearance in the whole left breast was observed. She was diagnosed with inflammatory breast cancer (luminal A type) T4dN2M0, Stage IIIB. The patient underwent primary systemic therapy with 7 courses of FEC. Following FEC treatment, the disease was stable. We subsequently administered 4 courses of bevacizumab plus paclitaxel combination therapy. The patient exhibited a partial response to FEC chemotherapy. Thereafter, a left mastectomy with level II axillary lymph node dissection was performed. At present, 1 year after surgery, the patient is alive with no recurrence. We conclude that the combination therapy of bevacizumab plus paclitaxel is a useful treatment for inflammatory breast cancer.